Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Faron Pharmaceuticals Oy (GB:FARN)
LSE:FARN
RESEARCH TOOLSreports
Holding GB:FARN?
Track your performance easily
FARN Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range85.00p - 306.08p
Previous Close152.5p
Volume20.49K
Average Volume (3M)19.40K
Market Cap
£164.15M
Enterprise Value169.40M
Total Cash (Recent Filing)€6.99M
Total Debt (Recent Filing)€13.27M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Mar 21, 2025EPS Estimate
-£0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding104,620,000
10 Day Avg. Volume8,277
30 Day Avg. Volume19,404
Standard Deviation0.24
R-Squared0.00019
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-1638.89
Price to Sales (P/S)593.27
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
537.55pPrice Target Upside252.49% Upside
Rating ConsensusHold
Number of Analyst Covering2
Faron Pharmaceuticals Oy News
PremiumCompany Announcements
Faron Pharmaceuticals Expands Pipeline with New Patent
PremiumCompany Announcements
Faron Pharmaceuticals Updates Nomination Board Amid Cancer Drug Trials
PremiumCompany Announcements
Faron Pharmaceuticals Reveals Promising Trial Results
PremiumCompany Announcements
Faron Pharmaceuticals Hosts Key Investor Event
PremiumCompany Announcements
Faron Pharmaceuticals Issues New Share Options
PremiumCompany Announcements
FDA Fast-Tracks Faron’s Bexmarilimab for r/r MDS
PremiumCompany Announcements
Faron Pharmaceuticals Rallies with Bexmarilimab Success
PremiumCompany Announcements
Faron Pharmaceuticals Announces H1 2024 FinancialsOptions Prices
Currently, No data available
---
Ownership Overview
FARN FAQ
What was Faron Pharmaceuticals Oy’s price range in the past 12 months?
Faron Pharmaceuticals Oy lowest share price was 85.00p and its highest was 306.08p in the past 12 months.
What is Faron Pharmaceuticals Oy’s market cap?
Currently, no data Available
When is Faron Pharmaceuticals Oy’s upcoming earnings report date?
Faron Pharmaceuticals Oy’s upcoming earnings report date is Mar 21, 2025 which is in 115 days.
How were Faron Pharmaceuticals Oy’s earnings last quarter?
Faron Pharmaceuticals Oy released its earnings results on Aug 27, 2024. The company reported -0.167p earnings per share for the quarter, beating the consensus estimate of -0.184p by 0.017p.
Is Faron Pharmaceuticals Oy overvalued?
According to Wall Street analysts Faron Pharmaceuticals Oy’s price is currently Undervalued.
Does Faron Pharmaceuticals Oy pay dividends?
Faron Pharmaceuticals Oy does not currently pay dividends.
What is Faron Pharmaceuticals Oy’s EPS estimate?
Faron Pharmaceuticals Oy’s EPS estimate is -£0.13.
How many shares outstanding does Faron Pharmaceuticals Oy have?
Faron Pharmaceuticals Oy has 104,624,860 shares outstanding.
What happened to Faron Pharmaceuticals Oy’s price movement after its last earnings report?
Faron Pharmaceuticals Oy reported an EPS of -0.167p in its last earnings report, beating expectations of -0.184p. Following the earnings report the stock price went up 24.855%.
Which hedge fund is a major shareholder of Faron Pharmaceuticals Oy?
Currently, no hedge funds are holding shares in GB:FARN
---
Faron Pharmaceuticals Oy Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
172.94%
Trailing 12-Months
Company Description
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is a anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.
---
FARN Stock 12 Month Forecast
Average Price Target
537.55p
▲(252.49% Upside)
Technical Analysis
Best Analysts Covering FARN
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-21.43%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -21.43% per trade.
---